

Editorial

Potential Applications of Nanomedicine

Hossein Hosseinkhani *

Innovation Center for Advanced Technology, Matrix HT, Inc., New York, NY 10019, USA; E-Mail:
hh@matrix-inc.com* Correspondence: Hossein Hosseinkhani; E-Mail: hh@matrix-inc.com

Recent Progress in Materials
2023, volume 5, issue 4
doi:10.21926/rpm.2304036

Received: December 03, 2023
Accepted: December 04, 2023
Published: December 05, 2023

Nanomedicine is new field of science that combines nanomaterials, biomaterials, and biology to generate new class of materials that are able to mimic human cells and tissues. Engineering nanomaterials products specifically biodegradable nanoparticles are great discoveries in the area of nanomedicine technology [1-20]. One strategy for engineering nanoscale materials is to design them in order to culture the cells inside the biomaterials such as natural or synthetic polymers [21-40]. Three dimensional (3D) scaffolding biomaterials are very applicable in tissue engineering and regenerative medicine [41-60]. Tissue engineering approaches is very useful to regenerate damaged tissue by combinational technology of nano-biomaterials and stem cells technology. Potential applications of nanomedicine technology are very wide and it covers wide range of therapeutic applications from drug discovery to smart diagnostic tools [61-70]. The drawbacks of biomedical devices are very costly and it takes very long time to bring a single product into the market. Therefore, it is critical to engineer such smart nanomaterials that are capable to address the needs for the emergent market in medicine [71-91]. Nanomedicine research could be carried out within a multiple year's period. It will be divided in three different individual projects (i.e. fabrication, investigation, and implementation) consisting of three different academic and technological tasks for each parts. The vision is transferring all regions into advanced technology to overcome the above problems by grooming local research talents and attracting top-rank scientists to develop the new technologies.



© 2023 by the author. This is an open access article distributed under the conditions of the [Creative Commons by Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.

Author Contributions

The author did all the research work of this study.

Competing Interests

The author has declared that no competing interests exist.

References

1. Hosseinkhani H, Tabata Y. Self assembly of DNA nanoparticles with polycations for the delivery of genetic materials into cells. *J Nanosci Nanotechnol*. 2006; 6: 2320-2328.
2. Hosseinkhani H, Azzam T, Tabata Y, Domb AJ. Dextran-spermine polycation: An efficient nonviral vector for in vitro and in vivo gene transfection. *Gene Ther*. 2004; 11: 194-203.
3. Abedini F, Hosseinkhani H, Ismail M, Chen YR, Omar A, Chong P, et al. In vitro intracellular trafficking of biodegradable nanoparticles dextran-spermine in cancer cell lines. *Int J Nanotechnol*. 2011; 8: 712-723.
4. Hosseinkhani H, Abedini F, Ou KL, Domb AJ. Polymers in gene therapy technology. *Polym Adv Technol*. 2015; 26: 198-211.
5. Abdullah S, Wendy-Yeo WY, Hosseinkhani H, Hosseinkhani M, Masrawa E, Ramasamy R, et al. Gene transfer into the lung by nanoparticle dextran-spermine/plasmid DNA complexes. *BioMed Res Int*. 2010; 2010: 284840.
6. Abedini F, Ismail M, Hosseinkhani H, Azmi T, Omar AR, Chong PP, et al. Toxicity evaluation of dextran-spermine polycation as a tool for genetherapy in vitro. *J Cell Anim Biol*. 2010; 4: 170-176.
7. Abedini F, Ismail M, Hosseinkhani H, Ibrahim TA, Omar AR, Chong PP, et al. Effects of CXCR4 siRNA/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver. *Cancer Manag Res*. 2011; 3: 301-309.
8. Yeo WW, Hosseinkhani H, Rahman SA, Rosli R, Domb AJ, Abdullah S. Safety profile of dextran-spermine gene delivery vector in mouse lungs. *J Nanosci Nanotechnol*. 2014; 14: 3328-3336.
9. Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Hosseinkhani H. In-vitro assessment of magnetic dextran-spermine nanoparticles for capecitabine delivery to cancerous cells. *Iran J Pharm Res*. 2017; 16: 1320-1334.
10. Jain A, Hosseinkhani H, Domb AJ, Khan W. Cationic polymers for the delivery of therapeutic nucleotides. In: *Polysaccharides*. Cham: Springer International Publishing Switzerland; 2015. pp. 1969-1990.
11. He W, Hosseinkhani H, Mohammadinejad R, Roveimiab Z, Hueng DY, Ou KL, et al. Polymeric nanoparticles for therapy and imaging. *Polym Adv Technol*. 2014; 25: 1216-1225.
12. Hosseinkhani H, Chen YR, He W, Hong PD, Yu DS, Domb AJ. Engineering of magnetic DNA nanoparticles for tumor-targeted therapy. *J Nanopart Res*. 2013; 15: 1345.
13. Hosseinkhani H, He WJ, Chiang CH, Hong PD, Yu DS, Domb AJ, et al. Biodegradable nanoparticles for gene therapy technology. *J Nanopart Res*. 2013; 15: 1794.
14. Amini R, Jalilian FA, Abdullah S, Veerakumarasivam A, Hosseinkhani H, Abdulamir AS, et al. Dynamics of PEGylated-dextran-spermine nanoparticles for gene delivery to leukemic cells. *Appl Biochem Biotechnol*. 2013; 170: 841-853.

15. He WJ, Hosseinkhani H, Hong PD, Chiang CH, Yu DS. Magnetic nanoparticles for imaging technology. *Int J Nanotechnol.* 2013; 10: 930-944.
16. Khan W, Hosseinkhani H, Ickowicz D, Hong PD, Yu DS, Domb AJ. Polysaccharide gene transfection agents. *Acta Biomater.* 2012; 8: 4224-4232.
17. Abedini F, Hosseinkhani H, Ismail M, Domb AJ, Omar AR, Chong PP, et al. Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer. *Int J Nanomedicine.* 2012; 7: 4159-4168.
18. Mohammad-Taheri M, Vasheghani-Farahani E, Hosseinkhani H, Shojaosadati SA, Soleimani M. Fabrication and characterization of a new MRI contrast agent based on a magnetic dextran-spermine nanoparticle system. *Iran Polym J.* 2012; 21: 239-251.
19. Amini R, Hosseinkhani H, Abdulamir AS, Rosli R, Jalilian FA. Engineered smart biomaterials for gene delivery. *Gene Ther Mol Biol.* 2012; 14: 72-86.
20. Hosseinkhani H, Hosseinkhani M, Chen YR, Subramani K, Domb AJ. Innovative technology of engineering magnetic DNA nanoparticles for gene therapy. *Int J Nanotechnol.* 2011; 8: 724-735.
21. Hosseinkhani M, Hosseinkhani H, Chen YR, Subramani K. In vitro physicochemical evaluation of DNA nanoparticles. *Int J Nanotechnol.* 2011; 8: 736-748.
22. Hosseinkhani H. DNA nanoparticles for gene delivery to cells and tissue. *Int J Nanotechnol.* 2006; 3: 416-461.
23. Abedini F, Ebrahimi M, Hosseinkhani H. Technology of RNA interference in advanced medicine. *MicroRNA.* 2018; 7: 74-84.
24. Abedini F, Ebrahimi M, Roozbehani AH, Domb AJ, Hosseinkhani H. Overview on natural hydrophilic polysaccharide polymers in drug delivery. *Polym Adv Technol.* 2018; 29: 2564-2573.
25. Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Mohamadyar-Toupkanlou F, Hosseinkhani H. Transferrin-conjugated magnetic dextran-spermine nanoparticles for targeted drug transport across blood-brain barrier. *J Biomed Mater Res A.* 2017; 105: 2851-2864.
26. Alibolandi M, Abnous K, Sadeghi F, Hosseinkhani H, Ramezani M, Hadizadeh F. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation. *Int J Pharm.* 2016; 500: 162-178.
27. Mottaghitalab F, Farokhi M, Shokrgozar MA, Atyabi F, Hosseinkhani H. Silk fibroin nanoparticle as a novel drug delivery system. *J Control Release.* 2015; 206: 161-176.
28. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: The state of investigational and approved nanomedicine products. *Nanomedicine.* 2013; 9: 1-14.
29. Alibolandi M, Abnous K, Ramezani M, Hosseinkhani H, Hadizadeh F. Synthesis of AS1411-aptamer-conjugated CdTe quantum dots with high fluorescence strength for probe labeling tumor cells. *J Fluoresc.* 2014; 24: 1519-1529.
30. Chiang CH, Hosseinkhani H, Cheng WS, Chen CW, Wang CH, Lo YL. Improving drug loading efficiency and delivery performance of micro-and nanoparticle preparations through optimising formulation variables. *Int J Nanotechnol.* 2013; 10: 996-1006.
31. Sarabi RS, Sadeghi EL, Hosseinkhani HO, Mahmoudi MO, Kalantari M, Adeli MO. Polyrotaxane capped quantum dots as new candidates for cancer diagnosis and therapy. *J Nanostructured Polym Nanocomposites.* 2011; 7: 18-31.

32. Domb AJ, Sharifzadeh G, Nahum V, Hosseinkhani H. Safety evaluation of nanotechnology products. *Pharmaceutics*. 2021; 13: 1615.
33. Steinman NY, Campos LM, Feng Y, Domb AJ, Hosseinkhani H. Cyclopropenium nanoparticles and gene transfection in cells. *Pharmaceutics*. 2020; 12: 768.
34. Hosseinkhani H, Domb AJ. Biodegradable polymers in gene-silencing technology. *Polyme Adv Technol*. 2019; 30: 2647-2655.
35. Hu CS, Tang SL, Chiang CH, Hosseinkhani H, Hong PD, Yeh MK. Characterization and anti-tumor effects of chondroitin sulfate–chitosan nanoparticles delivery system. *J Nanopart Res*. 2014; 16: 2672.
36. Hosseinkhani H., Hosseinkhani M., Khademhosseini A. Emerging technology of hydrogels in drug discovery. In: Topics in Multifunctional Biomaterials and Devices. Oulu: Oulu University; 2008.
37. Hosseinkhani H. Innovation technology to engineer 3D living organs as intelligent diagnostic tools. In: Characterization and development of biosystems and biomaterials. Berlin: Springer; 2013. pp. 183-192.
38. Hosseinkhani H, Hosseinkhani M. Biodegradable polymer-metal complexes for gene and drug delivery. *Curr Drug Saf*. 2009; 4: 79-83.
39. Mottaghitalab F, Rastegari A, Farokhi M, Dinarvand R, Hosseinkhani H, Ou KL, et al. Prospects of siRNA applications in regenerative medicine. *Int J Pharm*. 2017; 524: 312-329.
40. Hosseinkhani H, Domb AJ, Sharifzadeh G, Nahum V. Gene therapy for regenerative medicine. *Pharmaceutics*. 2023; 15: 856.
41. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y. Ultrasound enhances the transfection of plasmid DNA by non-viral vectors. *Curr Pharm Biotechnol*. 2003; 4: 109-122.
42. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y. Liver targeting of plasmid DNA by pullulan conjugation based on metal coordination. *J Control Release*. 2002; 83: 287-302.
43. Hosseinkhani H. siRNA delivery systems in cancer therapy. *Org Med Chem Int J*. 2020; 10: 1-3.
44. Dermani FK, Jalilian FA, Hossienkhani H, Ezati R, Amini R. SiRNA delivery technology for cancer therapy: Promise and challenges. *Acta Med Iran*. 2019; 57: 83-93.
45. Hosseinkhani H. Nanomaterials in advanced medicine. 1st ed. Weinheim, Germany: John Wiley & Sons; 2019. pp. 150-196.
46. Hosseinkhani H. Biomedical engineering: Materials, technology, and application. 1st ed. Weinheim, Germany: John Wiley & Sons; 2022. pp. 120-180.
47. Hosseinkhani H. Developing 3D technology for drug discovery. *Curr Drug Deliv*. 2022; 19: 813-814.
48. Hosseinkhani H, Inatsugu Y, Hiraoka Y, Inoue S, Shimokawa H, Tabata Y. Impregnation of plasmid DNA into three-dimensional scaffolds and medium perfusion enhance in vitro DNA expression of mesenchymal stem cells. *Tissue Eng*. 2005; 11: 1459-1475.
49. Farokhi M, Mottaghitalab F, Shokrgozar MA, Ou KL, Mao C, Hosseinkhani H. Importance of dual delivery systems for bone tissue engineering. *J Control Release*. 2016; 225: 152-169.
50. Mottaghitalab F, Hosseinkhani H, Shokrgozar MA, Mao C, Yang M, Farokhi M. Silk as a potential candidate for bone tissue engineering. *J Control Release*. 2015; 215: 112-128.
51. Hosseinkhani H, Hosseinkhani M, Gabrielson NP, Pack DW, Khademhosseini A, Kobayashi H. DNA nanoparticles encapsulated in 3D tissue-engineered scaffolds enhance osteogenic differentiation of mesenchymal stem cells. *J Biomed Mater Res A*. 2008; 85: 47-60.

52. Shahrezaei M, Habibzadeh S, Babaluo AA, Hosseinkhani H, Haghghi M, Hasanzadeh A, et al. Study of synthesis parameters and photocatalytic activity of TiO₂ nanostructures. *J Exp Nanosci.* 2017; 12: 45-61.
53. Hosseinkhani H, Chaswal V, Chang J, Shi D. The world scientific encyclopedia of nanomedicine and bioengineering I. 1st ed. Singapore: World Scientific Publishing Company; 2016. pp. 150-220.
54. Han HC, Lo HC, Wu CY, Chen KH, Chen LC, Ou KL, et al. Nano-textured fluidic biochip as biological filter for selective survival of neuronal cells. *J Biomed Mater Res A.* 2015; 103: 2015-2023.
55. Konishi M, Tabata Y, Kariya M, Hosseinkhani H, Suzuki A, Fukuhara K, et al. In vivo anti-tumor effect of dual release of cisplatin and Adriamycin from biodegradable gelatin hydrogel. *J Control Release.* 2005; 103: 7-19.
56. Hosseinkhani H. Controoled release system for bone regeneration. In: Polymeric biomaterials. 3rd ed. Boca Raton, FL: CRC Press; 2020. pp. 643-654.
57. Baheiraei N, Azami M, Hosseinkhani H. Investigation of magnesium incorporation within gelatin/calcium phosphate nanocomposite scaffold for bone tissue engineering. *Int J Appl Ceram Technol.* 2015; 12: 245-253.
58. Ou SF, Chen CS, Hosseinkhani H, Yu CH, Shen YD, Ou KL. Surface properties of nano-structural silicon-doped carbon films for biomedical applications. *Int J Nanotechnol.* 2013; 10: 945-958.
59. Hosseinkhani H. Special issue on nanomedicine. *Int J Nanotechnol.* 2011; 8: 615-617.
60. Hosseinkhani H, Chen KH. Special issue on nanotechnology research in Taiwan. *Int J Nanotechnol.* 2013; 10: 837-839.
61. Hosseinkhani H, Hosseinkhani M. Suppression effect of basic fibroblast growth factor on mesenchymal stem cell proliferation activity part I: Release characteristics. *Chem Today.* 2008; 26: 30-32.
62. Hosseinkhani H, Hosseinkhani M. Suppression effect of basic fibroblast growth factor on mesenchymal stem cell proliferation activity part II: Biological characteristics. *Chem Today.* 2008; 26: 35-37.
63. Khalaji S, Golshan Ebrahimi N, Hosseinkhani H. Enhancement of biocompatibility of PVA/HTCC blend polymer with collagen for skin care application. *Int J Polym Mater.* 2021; 70: 459-468.
64. Hosseini V, Maroufi NF, Saghati S, Asadi N, Darabi M, Ahmad SN, et al. Current progress in hepatic tissue regeneration by tissue engineering. *J Transl Med.* 2019; 17: 383.
65. Saberianpour S, Heidarzadeh M, Geranmayeh MH, Hosseinkhani H, Rahbarghazi R, Nouri M. Tissue engineering strategies for the induction of angiogenesis using biomaterials. *J Med Biol Eng.* 2018; 12: 36.
66. Toosi S, Naderi-Meshkin H, Kalalinia F, Pievandi MT, Hosseinkhani H, Bahrami AR, et al. Long bone mesenchymal stem cells (Lb-MSCs): Clinically reliable cells for osteo-diseases. *Cell Tissue Bank.* 2017; 18: 489-500.
67. Abbasi N, Hashemi SM, Salehi M, Jahani H, Mowla SJ, Soleimani M, et al. Influence of oriented nanofibrous PCL scaffolds on quantitative gene expression during neural differentiation of mouse embryonic stem cells. *J Biomed Mater Res A.* 2016; 104: 155-164.
68. Toosi S, Naderi-Meshkin H, Kalalinia F, Peivandi MT, Hosseinkhani H, Bahrami AR, et al. PGA-incorporated collagen: Toward a biodegradable composite scaffold for bone-tissue engineering. *J Biomed Mater Res A.* 2016; 104: 2020-2028.

69. Toosi S, Naderi-Meshkin H, Kalalinia F, Peivandi MT, Khani HH, Bahrami AR, et al. Comparative characteristics of mesenchymal stem cells derived from reamer-irrigator-aspirator, iliac crest bone marrow, and adipose tissue. *Cell Mol Biol.* 2016; 62: 68-74.
70. Jahani H, Jalilian FA, Wu CY, Kaviani S, Soleimani M, Abbasi N, et al. Controlled surface morphology and hydrophilicity of polycaprolactone toward selective differentiation of mesenchymal stem cells to neural like cells. *J Biomed Mater Res A.* 2015; 103: 1875-1881.
71. Rahbarghazi R, Nassiri SM, Ahmadi SH, Mohammadi E, Rabbani S, Araghi A, et al. Dynamic induction of pro-angiogenic milieu after transplantation of marrow-derived mesenchymal stem cells in experimental myocardial infarction. *Int J Cardiol.* 2014; 173: 453-466.
72. Ghodsizadeh A, Hosseinkhani H, Piryaei A, Pournasr B, Najarsl M, Hiraoka Y, et al. Galactosylated collagen matrix enhanced in vitro maturation of human embryonic stem cell-derived hepatocyte-like cells. *Biotechnol Lett.* 2014; 36: 1095-1106.
73. Shi D, Tatu R, Liu Q, Hosseinkhani H. Stem cell-based tissue engineering for regenerative medicine. *Nano Life.* 2014; 4: 1430001.
74. Ou KL, Hosseinkhani H. Development of 3D in vitro technology for medical applications. *Int J Mol Sci.* 2014; 15: 17938-17962.
75. Hosseinkhani H, Hong PD, Yu DS. Self-assembled proteins and peptides for regenerative medicine. *Chem Rev.* 2013; 113: 4837-4861.
76. Hosseinkhani H, Hiraoka Y, Li CH, Chen YR, Yu DS, Hong PD, et al. Engineering three-dimensional collagen-IKVAV matrix to mimic neural microenvironment. *ACS Chem Neurosci.* 2013; 4: 1229-1235.
77. Hosseinkhani H. 3D in vitro technology for drug discovery. *Curr Drug Saf.* 2012; 7: 37-43.
78. Subramani K, Mathew R, Hosseinkhani H, Hosseinkhani M. Bone regeneration around dental implants as a treatment for peri-implantitis: A review of the literature. *J Biomimetics Biomater Tissue Eng.* 2011; 11: 21-33.
79. Hosseinkhani H, Hosseinkhani M, Hattori S, Matsuoka R, Kawaguchi N. Micro and nano-scale in vitro 3D culture system for cardiac stem cells. *J Biomed Mater Res A.* 2010; 94: 1-8.
80. Mohajeri S, Hosseinkhani H, Golshan Ebrahimi N, Nikfarjam L, Soleimani M, Kajbafzadeh AM. Proliferation and differentiation of mesenchymal stem cell on collagen sponge reinforced with polypropylene/polyethylene terephthalate blend fibers. *Tissue Eng Part A.* 2010; 16: 3821-3830.
81. Tian F, Hosseinkhani H, Hosseinkhani M, Khademhosseini A, Yokoyama Y, Estrada GG, et al. Quantitative analysis of cell adhesion on aligned micro-and nanofibers. *J Biomed Mater Res A.* 2008; 84: 291-299.
82. Hosseinkhani H, Hosseinkhani M, Tian F, Kobayashi H, Tabata Y. Osteogenic differentiation of mesenchymal stem cells in self-assembled peptide-amphiphile nanofibers. *Biomaterials.* 2006; 27: 4079-4086.
83. Hosseinkhani H, Azzam T, Kobayashi H, Hiraoka Y, Shimokawa H, Domb AJ, et al. Combination of 3D tissue engineered scaffold and non-viral gene carrier enhance in vitro DNA expression of mesenchymal stem cells. *Biomaterials.* 2006; 27: 4269-4278.
84. Hosseinkhani H, Hosseinkhani M, Tian F, Kobayashi H, Tabata Y. Ectopic bone formation in collagen sponge self-assembled peptide–amphiphile nanofibers hybrid scaffold in a perfusion culture bioreactor. *Biomaterials.* 2006; 27: 5089-5098.

85. Hosseinkhani H, Hosseinkhani M, Khademhosseini A, Kobayashi H, Tabata Y. Enhanced angiogenesis through controlled release of basic fibroblast growth factor from peptide amphiphile for tissue regeneration. *Biomaterials*. 2006; 27: 5836-5844.
86. Hosseinkhani H, Hosseinkhani M, Kobayashi H. Proliferation and differentiation of mesenchymal stem cells using self-assembled peptide amphiphile nanofibers. *Biomed Mater*. 2006; 1: 8.
87. Hosseinkhani H, Hosseinkhani M, Kobayashi H. Design of tissue-engineered nanoscaffold through self-assembly of peptide amphiphile. *J Bioact Compat Polym*. 2006; 21: 277-296.
88. Hosseinkhani H, Hosseinkhani M, Khademhosseini A. Emerging applications of hydrogels and microscale technologies in drug discovery. *Drug Discov*. 2006; 1: 32-34.
89. Hosseinkhani H, Inatsugu Y, Hiraoka Y, Inoue S, Tabata Y. Perfusion culture enhances osteogenic differentiation of rat mesenchymal stem cells in collagen sponge reinforced with poly (glycolic acid) fiber. *Tissue Eng*. 2005; 11: 1476-1488.
90. Hosseinkhani H, Hong PD, Yu DS, Chen YR, Ickowicz D, Farber IY, et al. Development of 3D in vitro platform technology to engineer mesenchymal stem cells. *In J Nanomedicine*. 2012; 7: 3035-3043.
91. Sharifzadeh G, Hosseinkhani H. Biomolecule-responsive hydrogels in medicine. *Adv Healthcare Mater*. 2017; 6: 1700801.